
    
      This study was terminated on 19 Apr 2010 due to unfavorable risk benefit ratio which did not
      support continuation in part 2 of the study. Even if the safety profile of the combination of
      Bosutinib and Exemestane was acceptable 25% of subjects had treatment related liver events
      including 14% of severe liver events.
    
  